^
Association details:
| Biomarker: | MSI-H/dMMR |
|---|---|
| Cancer: | Colorectal Cancer |
| Drug: | Loqtorzi (toripalimab-tpzi) (PD1 inhibitor) + celecoxib (DRGT-46) (COX2 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Neoadjuvant PD-1 blockade with toripalimab, with or without celecoxib, in mismatch repair-deficient or microsatellite instability-high, locally advanced, colorectal cancer (PICC): a single-centre, parallel-group, non-comparative, randomised, phase 2 trial
Published date:
10/21/2021
Excerpt:
15 of 17 patients (88% [95% CI 64–99]) in the toripalimab plus celecoxib group and 11 of 17 patients (65% [38–86]) in the toripalimab monotherapy group had a pathological complete response...Neoadjuvant toripalimab with or without celecoxib could be a potential therapeutic option for patients with mismatch repair deficient or microsatellite instability-high, locally advanced, colorectal cancer. This treatment was associated with a high pathological complete response rate...
DOI:
https://doi.org/10.1016/S2468-1253(21)00348-4
Trial ID:
